A 6-Month clinical practice pilot study of sucroferric oxyhydroxide on nutritional status in patients on peritoneal dialysis View Full Text


Ontology type: schema:ScholarlyArticle      Open Access: True


Article Info

DATE

2022-07-09

AUTHORS

Luis Perez, Zhiying You, Isaac Teitelbaum, Emily S Andrews, Rachael Reddin, Lorena Ramirez-Renteria, Gabriela Wilson, Jessica Kendrick

ABSTRACT

BackgroundHyperphosphatemia is common in patients on peritoneal dialysis (PD). Restricting dietary phosphorus often leads to a decrease in protein intake, which may result in hypoalbuminemia. The high pill burden of phosphate binders may also contribute to compromised appetite and dietary intake. Hypoalbuminemia is associated with an increased risk of morbidity and mortality in PD patients. The goal of this study was to determine if sucroferric oxyhydroxide improves albumin and self-reported measures of appetite in PD patients.MethodsWe performed a prospective, open-label, 6-month, pilot study of 17 adult PD patients from the Denver Metro Area. Patients had to use automated peritoneal dialysis for ≥ 3 months, have a serum albumin ≤ 3.8 g/dL, and have serum phosphate ≥ 5.5 mg/dL or ≤ 5.5 mg/dL on a binder other than SO. SO was titrated to a goal serum phosphate of < 5.5 mg/dL. The primary outcome was change in serum phosphate, albumin, and phosphorus-attuned albumin (defined as albumin divided by phosphorus) over 6 months.ResultsThe mean (SD) age and dialysis vintage was 55 ± 13 years and 3.8 ± 2.7 years, respectively. Participants’ serum phosphate significantly decreased with fewer phosphate binder pills/day after switching to SO. There was no change in serum albumin, appetite, or dietary intake. However, participants had significant improvements in phosphorus-attuned albumin.ConclusionThe transition to SO improved phosphorus control, phosphorus-attuned albumin, and pill burden. There were no significant changes in self-reported appetite or dietary intake during the study. These findings suggest that PD patients maintained nutritional status with SO therapy.Trial registrationFirst registered at ClinicalTrials.gov (NCT04046263) on 06/08/2019. More... »

PAGES

245

Identifiers

URI

http://scigraph.springernature.com/pub.10.1186/s12882-022-02878-5

DOI

http://dx.doi.org/10.1186/s12882-022-02878-5

DIMENSIONS

https://app.dimensions.ai/details/publication/pub.1149361125

PUBMED

https://www.ncbi.nlm.nih.gov/pubmed/35810296


Indexing Status Check whether this publication has been indexed by Scopus and Web Of Science using the SN Indexing Status Tool
Incoming Citations Browse incoming citations for this publication using opencitations.net

JSON-LD is the canonical representation for SciGraph data.

TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

[
  {
    "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
    "about": [
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/11", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Medical and Health Sciences", 
        "type": "DefinedTerm"
      }, 
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1103", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Clinical Sciences", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Adult", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Aged", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Drug Combinations", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Ferric Compounds", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Humans", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Hyperphosphatemia", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Hypoalbuminemia", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Middle Aged", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Nutritional Status", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Peritoneal Dialysis", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Phosphates", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Phosphorus", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Pilot Projects", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Prospective Studies", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Serum Albumin", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Sucrose", 
        "type": "DefinedTerm"
      }
    ], 
    "author": [
      {
        "affiliation": {
          "alternateName": "Division of Renal Diseases and Hypertension, University of Colorado Anschutz Medical Campus, 80045, Aurora, CO, USA", 
          "id": "http://www.grid.ac/institutes/grid.430503.1", 
          "name": [
            "Division of Renal Diseases and Hypertension, University of Colorado Anschutz Medical Campus, 80045, Aurora, CO, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Perez", 
        "givenName": "Luis", 
        "id": "sg:person.013674012200.16", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.013674012200.16"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Division of Renal Diseases and Hypertension, University of Colorado Anschutz Medical Campus, 80045, Aurora, CO, USA", 
          "id": "http://www.grid.ac/institutes/grid.430503.1", 
          "name": [
            "Division of Renal Diseases and Hypertension, University of Colorado Anschutz Medical Campus, 80045, Aurora, CO, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "You", 
        "givenName": "Zhiying", 
        "id": "sg:person.015701004515.29", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.015701004515.29"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Division of Renal Diseases and Hypertension, University of Colorado Anschutz Medical Campus, 80045, Aurora, CO, USA", 
          "id": "http://www.grid.ac/institutes/grid.430503.1", 
          "name": [
            "Division of Renal Diseases and Hypertension, University of Colorado Anschutz Medical Campus, 80045, Aurora, CO, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Teitelbaum", 
        "givenName": "Isaac", 
        "id": "sg:person.0775663733.53", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0775663733.53"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Division of Renal Diseases and Hypertension, University of Colorado Anschutz Medical Campus, 80045, Aurora, CO, USA", 
          "id": "http://www.grid.ac/institutes/grid.430503.1", 
          "name": [
            "Division of Renal Diseases and Hypertension, University of Colorado Anschutz Medical Campus, 80045, Aurora, CO, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Andrews", 
        "givenName": "Emily S", 
        "id": "sg:person.014304115177.88", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.014304115177.88"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Division of Renal Diseases and Hypertension, University of Colorado Anschutz Medical Campus, 80045, Aurora, CO, USA", 
          "id": "http://www.grid.ac/institutes/grid.430503.1", 
          "name": [
            "Division of Renal Diseases and Hypertension, University of Colorado Anschutz Medical Campus, 80045, Aurora, CO, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Reddin", 
        "givenName": "Rachael", 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Division of Renal Diseases and Hypertension, University of Colorado Anschutz Medical Campus, 80045, Aurora, CO, USA", 
          "id": "http://www.grid.ac/institutes/grid.430503.1", 
          "name": [
            "Division of Renal Diseases and Hypertension, University of Colorado Anschutz Medical Campus, 80045, Aurora, CO, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Ramirez-Renteria", 
        "givenName": "Lorena", 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Division of Renal Diseases and Hypertension, University of Colorado Anschutz Medical Campus, 80045, Aurora, CO, USA", 
          "id": "http://www.grid.ac/institutes/grid.430503.1", 
          "name": [
            "Division of Renal Diseases and Hypertension, University of Colorado Anschutz Medical Campus, 80045, Aurora, CO, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Wilson", 
        "givenName": "Gabriela", 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Division of Renal Diseases and Hypertension, University of Colorado Anschutz Medical Campus, 80045, Aurora, CO, USA", 
          "id": "http://www.grid.ac/institutes/grid.430503.1", 
          "name": [
            "Division of Renal Diseases and Hypertension, University of Colorado Anschutz Medical Campus, 80045, Aurora, CO, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Kendrick", 
        "givenName": "Jessica", 
        "id": "sg:person.0670421736.19", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0670421736.19"
        ], 
        "type": "Person"
      }
    ], 
    "citation": [
      {
        "id": "sg:pub.10.1186/s12882-019-1582-9", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1122168042", 
          "https://doi.org/10.1186/s12882-019-1582-9"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/s40620-021-01241-5", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1145402178", 
          "https://doi.org/10.1007/s40620-021-01241-5"
        ], 
        "type": "CreativeWork"
      }
    ], 
    "datePublished": "2022-07-09", 
    "datePublishedReg": "2022-07-09", 
    "description": "BackgroundHyperphosphatemia is common in patients on peritoneal dialysis (PD). Restricting dietary phosphorus often leads to a decrease in protein intake, which may result in hypoalbuminemia. The high pill burden of phosphate binders may also contribute to compromised appetite and dietary intake. Hypoalbuminemia is associated with an increased risk of morbidity and mortality in PD patients. The goal of this study was to determine if sucroferric oxyhydroxide improves albumin and self-reported measures of appetite in PD patients.MethodsWe performed a prospective, open-label, 6-month, pilot study of 17 adult PD patients from the Denver Metro Area. Patients had to use automated peritoneal dialysis for\u2009\u2265\u20093\u00a0months,\u00a0have a serum albumin\u2009\u2264\u20093.8\u00a0g/dL, and have serum phosphate\u2009\u2265\u20095.5\u00a0mg/dL or\u2009\u2264\u20095.5\u00a0mg/dL on a binder other than SO. SO was titrated to a goal serum phosphate of\u2009<\u20095.5\u00a0mg/dL. The primary outcome was change in serum phosphate, albumin, and phosphorus-attuned albumin (defined as albumin divided by phosphorus) over 6\u00a0months.ResultsThe mean (SD) age and dialysis vintage was 55\u2009\u00b1\u200913\u00a0years and 3.8\u2009\u00b1\u20092.7\u00a0years, respectively. Participants\u2019 serum phosphate significantly decreased with fewer phosphate binder pills/day after switching to SO. There was no change in serum albumin, appetite, or dietary intake. However, participants had significant improvements in phosphorus-attuned albumin.ConclusionThe transition to SO improved phosphorus control, phosphorus-attuned albumin, and pill burden. There were no significant changes in self-reported appetite or dietary intake during the study. These findings suggest that PD patients maintained nutritional status with SO therapy.Trial registrationFirst registered at ClinicalTrials.gov (NCT04046263) on 06/08/2019.", 
    "genre": "article", 
    "id": "sg:pub.10.1186/s12882-022-02878-5", 
    "isAccessibleForFree": true, 
    "isPartOf": [
      {
        "id": "sg:journal.1024626", 
        "issn": [
          "1471-2369"
        ], 
        "name": "BMC Nephrology", 
        "publisher": "Springer Nature", 
        "type": "Periodical"
      }, 
      {
        "issueNumber": "1", 
        "type": "PublicationIssue"
      }, 
      {
        "type": "PublicationVolume", 
        "volumeNumber": "23"
      }
    ], 
    "keywords": [
      "serum phosphate", 
      "peritoneal dialysis", 
      "PD patients", 
      "dietary intake", 
      "pill burden", 
      "sucroferric oxyhydroxide", 
      "nutritional status", 
      "pilot study", 
      "pills/day", 
      "high pill burden", 
      "ResultsThe mean age", 
      "risk of morbidity", 
      "adult PD patients", 
      "self-reported appetite", 
      "dialysis vintage", 
      "primary outcome", 
      "mean age", 
      "phosphate binders", 
      "Denver metro area", 
      "patients", 
      "protein intake", 
      "dietary phosphorus", 
      "intake", 
      "appetite", 
      "serum albumin", 
      "dl", 
      "dialysis", 
      "hypoalbuminemia", 
      "self-report measures", 
      "albumin", 
      "months", 
      "significant changes", 
      "burden", 
      "significant improvement", 
      "phosphorus control", 
      "status", 
      "BackgroundHyperphosphatemia", 
      "participants", 
      "morbidity", 
      "therapy", 
      "mortality", 
      "years", 
      "MethodsWe", 
      "study", 
      "outcomes", 
      "age", 
      "risk", 
      "changes", 
      "days", 
      "findings", 
      "decrease", 
      "control", 
      "phosphate", 
      "measures", 
      "metro area", 
      "improvement", 
      "vintage", 
      "area", 
      "goal", 
      "SO", 
      "phosphorus", 
      "binder", 
      "transition", 
      "oxyhydroxides"
    ], 
    "name": "A 6-Month clinical practice pilot study of sucroferric oxyhydroxide on nutritional status in patients on peritoneal dialysis", 
    "pagination": "245", 
    "productId": [
      {
        "name": "dimensions_id", 
        "type": "PropertyValue", 
        "value": [
          "pub.1149361125"
        ]
      }, 
      {
        "name": "doi", 
        "type": "PropertyValue", 
        "value": [
          "10.1186/s12882-022-02878-5"
        ]
      }, 
      {
        "name": "pubmed_id", 
        "type": "PropertyValue", 
        "value": [
          "35810296"
        ]
      }
    ], 
    "sameAs": [
      "https://doi.org/10.1186/s12882-022-02878-5", 
      "https://app.dimensions.ai/details/publication/pub.1149361125"
    ], 
    "sdDataset": "articles", 
    "sdDatePublished": "2022-09-02T16:07", 
    "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
    "sdPublisher": {
      "name": "Springer Nature - SN SciGraph project", 
      "type": "Organization"
    }, 
    "sdSource": "s3://com-springernature-scigraph/baseset/20220902/entities/gbq_results/article/article_938.jsonl", 
    "type": "ScholarlyArticle", 
    "url": "https://doi.org/10.1186/s12882-022-02878-5"
  }
]
 

Download the RDF metadata as:  json-ld nt turtle xml License info

HOW TO GET THIS DATA PROGRAMMATICALLY:

JSON-LD is a popular format for linked data which is fully compatible with JSON.

curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/pub.10.1186/s12882-022-02878-5'

N-Triples is a line-based linked data format ideal for batch operations.

curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/pub.10.1186/s12882-022-02878-5'

Turtle is a human-readable linked data format.

curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/pub.10.1186/s12882-022-02878-5'

RDF/XML is a standard XML format for linked data.

curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/pub.10.1186/s12882-022-02878-5'


 

This table displays all metadata directly associated to this object as RDF triples.

242 TRIPLES      21 PREDICATES      107 URIs      97 LITERALS      23 BLANK NODES

Subject Predicate Object
1 sg:pub.10.1186/s12882-022-02878-5 schema:about N12cbf562a56f4170babdcd126ae6560e
2 N1906530c86634950b0434078c4c33fb8
3 N1b4789ced7684c4bb9452821f5ff0c33
4 N2cbe2aba83ed4e0482440b8e3826d9f9
5 N2fce028b9a4848519d5afbcee8c66870
6 N308092e479a84d8ca0e97183842ac144
7 N32b0906e1bea4140afcff77c7d284255
8 N47f05c72e7c34e07997ce31104befb6f
9 N4d8ecaf2435f408bbd5d3c2b1ec44129
10 N6b467f3e3b284fdab96fd4e0da292f9e
11 N72c4373fc0a549219698c875449d3191
12 Na0d682a337c0453d82147e24085dac08
13 Nb02a0f2ef6f44cd4b4acf8666e3b64fc
14 Nb557dd96c68d4e34ae657d7d41bd9ae8
15 Ndb04113b71e14c24a53677e7e64d174e
16 Ne73560112c8d49b2bb12e0c3b7bb10a7
17 anzsrc-for:11
18 anzsrc-for:1103
19 schema:author Na2bdee2ae3a240518780da6d20e8baf5
20 schema:citation sg:pub.10.1007/s40620-021-01241-5
21 sg:pub.10.1186/s12882-019-1582-9
22 schema:datePublished 2022-07-09
23 schema:datePublishedReg 2022-07-09
24 schema:description BackgroundHyperphosphatemia is common in patients on peritoneal dialysis (PD). Restricting dietary phosphorus often leads to a decrease in protein intake, which may result in hypoalbuminemia. The high pill burden of phosphate binders may also contribute to compromised appetite and dietary intake. Hypoalbuminemia is associated with an increased risk of morbidity and mortality in PD patients. The goal of this study was to determine if sucroferric oxyhydroxide improves albumin and self-reported measures of appetite in PD patients.MethodsWe performed a prospective, open-label, 6-month, pilot study of 17 adult PD patients from the Denver Metro Area. Patients had to use automated peritoneal dialysis for ≥ 3 months, have a serum albumin ≤ 3.8 g/dL, and have serum phosphate ≥ 5.5 mg/dL or ≤ 5.5 mg/dL on a binder other than SO. SO was titrated to a goal serum phosphate of < 5.5 mg/dL. The primary outcome was change in serum phosphate, albumin, and phosphorus-attuned albumin (defined as albumin divided by phosphorus) over 6 months.ResultsThe mean (SD) age and dialysis vintage was 55 ± 13 years and 3.8 ± 2.7 years, respectively. Participants’ serum phosphate significantly decreased with fewer phosphate binder pills/day after switching to SO. There was no change in serum albumin, appetite, or dietary intake. However, participants had significant improvements in phosphorus-attuned albumin.ConclusionThe transition to SO improved phosphorus control, phosphorus-attuned albumin, and pill burden. There were no significant changes in self-reported appetite or dietary intake during the study. These findings suggest that PD patients maintained nutritional status with SO therapy.Trial registrationFirst registered at ClinicalTrials.gov (NCT04046263) on 06/08/2019.
25 schema:genre article
26 schema:isAccessibleForFree true
27 schema:isPartOf N39736188421a4325a8fa7e72cdb7d64e
28 N46fa4685df9e4118999ecab669da2646
29 sg:journal.1024626
30 schema:keywords BackgroundHyperphosphatemia
31 Denver metro area
32 MethodsWe
33 PD patients
34 ResultsThe mean age
35 SO
36 adult PD patients
37 age
38 albumin
39 appetite
40 area
41 binder
42 burden
43 changes
44 control
45 days
46 decrease
47 dialysis
48 dialysis vintage
49 dietary intake
50 dietary phosphorus
51 dl
52 findings
53 goal
54 high pill burden
55 hypoalbuminemia
56 improvement
57 intake
58 mean age
59 measures
60 metro area
61 months
62 morbidity
63 mortality
64 nutritional status
65 outcomes
66 oxyhydroxides
67 participants
68 patients
69 peritoneal dialysis
70 phosphate
71 phosphate binders
72 phosphorus
73 phosphorus control
74 pill burden
75 pills/day
76 pilot study
77 primary outcome
78 protein intake
79 risk
80 risk of morbidity
81 self-report measures
82 self-reported appetite
83 serum albumin
84 serum phosphate
85 significant changes
86 significant improvement
87 status
88 study
89 sucroferric oxyhydroxide
90 therapy
91 transition
92 vintage
93 years
94 schema:name A 6-Month clinical practice pilot study of sucroferric oxyhydroxide on nutritional status in patients on peritoneal dialysis
95 schema:pagination 245
96 schema:productId N1e0844d912c44d0a918f288d5cd3fafd
97 N6250313d75ca48f79c62589b80077a6d
98 Nf4fbec8187d54346bc6bfc5c1f525927
99 schema:sameAs https://app.dimensions.ai/details/publication/pub.1149361125
100 https://doi.org/10.1186/s12882-022-02878-5
101 schema:sdDatePublished 2022-09-02T16:07
102 schema:sdLicense https://scigraph.springernature.com/explorer/license/
103 schema:sdPublisher Na207737fde1246b8ae634a24cc2dda23
104 schema:url https://doi.org/10.1186/s12882-022-02878-5
105 sgo:license sg:explorer/license/
106 sgo:sdDataset articles
107 rdf:type schema:ScholarlyArticle
108 N01235cdaa5274926bb8a2bdf0febd9cb rdf:first Nb8256ab88f7c4719a337b280d30b48e6
109 rdf:rest N77424c4a6db94bd18ee9dcc8f463a4e4
110 N12cbf562a56f4170babdcd126ae6560e schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
111 schema:name Humans
112 rdf:type schema:DefinedTerm
113 N1906530c86634950b0434078c4c33fb8 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
114 schema:name Sucrose
115 rdf:type schema:DefinedTerm
116 N1a80656ce29f42cfbb24856ca26d2956 rdf:first sg:person.015701004515.29
117 rdf:rest N2f6931217a2341df87d4e93f4b6c5f8c
118 N1b4789ced7684c4bb9452821f5ff0c33 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
119 schema:name Hypoalbuminemia
120 rdf:type schema:DefinedTerm
121 N1e0844d912c44d0a918f288d5cd3fafd schema:name doi
122 schema:value 10.1186/s12882-022-02878-5
123 rdf:type schema:PropertyValue
124 N2cbe2aba83ed4e0482440b8e3826d9f9 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
125 schema:name Adult
126 rdf:type schema:DefinedTerm
127 N2f6931217a2341df87d4e93f4b6c5f8c rdf:first sg:person.0775663733.53
128 rdf:rest Nbfdf324504ac42d09799f5115204554f
129 N2fce028b9a4848519d5afbcee8c66870 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
130 schema:name Ferric Compounds
131 rdf:type schema:DefinedTerm
132 N308092e479a84d8ca0e97183842ac144 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
133 schema:name Nutritional Status
134 rdf:type schema:DefinedTerm
135 N32b0906e1bea4140afcff77c7d284255 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
136 schema:name Peritoneal Dialysis
137 rdf:type schema:DefinedTerm
138 N39736188421a4325a8fa7e72cdb7d64e schema:volumeNumber 23
139 rdf:type schema:PublicationVolume
140 N431307ed5a474f7c97547ce88c4df2ac rdf:first sg:person.0670421736.19
141 rdf:rest rdf:nil
142 N46fa4685df9e4118999ecab669da2646 schema:issueNumber 1
143 rdf:type schema:PublicationIssue
144 N47f05c72e7c34e07997ce31104befb6f schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
145 schema:name Serum Albumin
146 rdf:type schema:DefinedTerm
147 N4ae67bc41ae64f4f9e43a13c051d8493 rdf:first Ne48dd36976ab400d90722366d466cea9
148 rdf:rest N01235cdaa5274926bb8a2bdf0febd9cb
149 N4d8ecaf2435f408bbd5d3c2b1ec44129 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
150 schema:name Prospective Studies
151 rdf:type schema:DefinedTerm
152 N6250313d75ca48f79c62589b80077a6d schema:name dimensions_id
153 schema:value pub.1149361125
154 rdf:type schema:PropertyValue
155 N6b467f3e3b284fdab96fd4e0da292f9e schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
156 schema:name Phosphorus
157 rdf:type schema:DefinedTerm
158 N72c4373fc0a549219698c875449d3191 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
159 schema:name Hyperphosphatemia
160 rdf:type schema:DefinedTerm
161 N77424c4a6db94bd18ee9dcc8f463a4e4 rdf:first Nc151a47dcb34431aae096388c4c794d5
162 rdf:rest N431307ed5a474f7c97547ce88c4df2ac
163 Na0d682a337c0453d82147e24085dac08 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
164 schema:name Middle Aged
165 rdf:type schema:DefinedTerm
166 Na207737fde1246b8ae634a24cc2dda23 schema:name Springer Nature - SN SciGraph project
167 rdf:type schema:Organization
168 Na2bdee2ae3a240518780da6d20e8baf5 rdf:first sg:person.013674012200.16
169 rdf:rest N1a80656ce29f42cfbb24856ca26d2956
170 Nb02a0f2ef6f44cd4b4acf8666e3b64fc schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
171 schema:name Drug Combinations
172 rdf:type schema:DefinedTerm
173 Nb557dd96c68d4e34ae657d7d41bd9ae8 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
174 schema:name Phosphates
175 rdf:type schema:DefinedTerm
176 Nb8256ab88f7c4719a337b280d30b48e6 schema:affiliation grid-institutes:grid.430503.1
177 schema:familyName Ramirez-Renteria
178 schema:givenName Lorena
179 rdf:type schema:Person
180 Nbfdf324504ac42d09799f5115204554f rdf:first sg:person.014304115177.88
181 rdf:rest N4ae67bc41ae64f4f9e43a13c051d8493
182 Nc151a47dcb34431aae096388c4c794d5 schema:affiliation grid-institutes:grid.430503.1
183 schema:familyName Wilson
184 schema:givenName Gabriela
185 rdf:type schema:Person
186 Ndb04113b71e14c24a53677e7e64d174e schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
187 schema:name Aged
188 rdf:type schema:DefinedTerm
189 Ne48dd36976ab400d90722366d466cea9 schema:affiliation grid-institutes:grid.430503.1
190 schema:familyName Reddin
191 schema:givenName Rachael
192 rdf:type schema:Person
193 Ne73560112c8d49b2bb12e0c3b7bb10a7 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
194 schema:name Pilot Projects
195 rdf:type schema:DefinedTerm
196 Nf4fbec8187d54346bc6bfc5c1f525927 schema:name pubmed_id
197 schema:value 35810296
198 rdf:type schema:PropertyValue
199 anzsrc-for:11 schema:inDefinedTermSet anzsrc-for:
200 schema:name Medical and Health Sciences
201 rdf:type schema:DefinedTerm
202 anzsrc-for:1103 schema:inDefinedTermSet anzsrc-for:
203 schema:name Clinical Sciences
204 rdf:type schema:DefinedTerm
205 sg:journal.1024626 schema:issn 1471-2369
206 schema:name BMC Nephrology
207 schema:publisher Springer Nature
208 rdf:type schema:Periodical
209 sg:person.013674012200.16 schema:affiliation grid-institutes:grid.430503.1
210 schema:familyName Perez
211 schema:givenName Luis
212 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.013674012200.16
213 rdf:type schema:Person
214 sg:person.014304115177.88 schema:affiliation grid-institutes:grid.430503.1
215 schema:familyName Andrews
216 schema:givenName Emily S
217 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.014304115177.88
218 rdf:type schema:Person
219 sg:person.015701004515.29 schema:affiliation grid-institutes:grid.430503.1
220 schema:familyName You
221 schema:givenName Zhiying
222 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.015701004515.29
223 rdf:type schema:Person
224 sg:person.0670421736.19 schema:affiliation grid-institutes:grid.430503.1
225 schema:familyName Kendrick
226 schema:givenName Jessica
227 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0670421736.19
228 rdf:type schema:Person
229 sg:person.0775663733.53 schema:affiliation grid-institutes:grid.430503.1
230 schema:familyName Teitelbaum
231 schema:givenName Isaac
232 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0775663733.53
233 rdf:type schema:Person
234 sg:pub.10.1007/s40620-021-01241-5 schema:sameAs https://app.dimensions.ai/details/publication/pub.1145402178
235 https://doi.org/10.1007/s40620-021-01241-5
236 rdf:type schema:CreativeWork
237 sg:pub.10.1186/s12882-019-1582-9 schema:sameAs https://app.dimensions.ai/details/publication/pub.1122168042
238 https://doi.org/10.1186/s12882-019-1582-9
239 rdf:type schema:CreativeWork
240 grid-institutes:grid.430503.1 schema:alternateName Division of Renal Diseases and Hypertension, University of Colorado Anschutz Medical Campus, 80045, Aurora, CO, USA
241 schema:name Division of Renal Diseases and Hypertension, University of Colorado Anschutz Medical Campus, 80045, Aurora, CO, USA
242 rdf:type schema:Organization
 




Preview window. Press ESC to close (or click here)


...